-
Kenya's economy faces climate change risks: World Bank
-
EU eyes migration clampdown with push on deportations, visas
-
Northern Mozambique: massive gas potential in an insurgency zone
-
Gold demand hits record high on Trump policy doubts: industry
-
UK drugs giant AstraZeneca announces $15 bn investment in China
-
Ghana moves to rewrite mining laws for bigger share of gold revenues
-
Russia's sanctioned oil firm Lukoil to sell foreign assets to Carlyle
-
Gold soars towards $5,600 as Trump rattles sabre over Iran
-
Deutsche Bank logs record profits, as new probe casts shadow
-
Vietnam and EU upgrade ties as EU chief visits Hanoi
-
Hongkongers snap up silver as gold becomes 'too expensive'
-
Gold soars past $5,500 as Trump sabre rattles over Iran
-
Samsung logs best-ever profit on AI chip demand
-
China's ambassador warns Australia on buyback of key port
-
As US tensions churn, new generation of protest singers meet the moment
-
Venezuelans eye economic revival with hoped-for oil resurgence
-
Samsung Electronics posts record profit on AI demand
-
French Senate adopts bill to return colonial-era art
-
Tesla profits tumble on lower EV sales, AI spending surge
-
Meta shares jump on strong earnings report
-
Anti-immigration protesters force climbdown in Sundance documentary
-
Springsteen releases fiery ode to Minneapolis shooting victims
-
SpaceX eyes IPO timed to planet alignment and Musk birthday: report
-
Neil Young gifts music to Greenland residents for stress relief
-
Fear in Sicilian town as vast landslide risks widening
-
King Charles III warns world 'going backwards' in climate fight
-
Court orders Dutch to protect Caribbean island from climate change
-
Rules-based trade with US is 'over': Canada central bank head
-
Holocaust survivor urges German MPs to tackle resurgent antisemitism
-
'Extraordinary' trove of ancient species found in China quarry
-
Google unveils AI tool probing mysteries of human genome
-
UK proposes to let websites refuse Google AI search
-
Trump says 'time running out' as Iran threatens tough response
-
Germany cuts growth forecast as recovery slower than hoped
-
Amazon to cut 16,000 jobs worldwide
-
Greenland dispute is 'wake-up call' for Europe: Macron
-
Dollar halts descent, gold keeps climbing before Fed update
-
Sweden plans to ban mobile phones in schools
-
Deutsche Bank offices searched in money laundering probe
-
Susan Sarandon to be honoured at Spain's top film awards
-
Trump says 'time running out' as Iran rejects talks amid 'threats'
-
Spain eyes full service on train tragedy line in 10 days
-
Greenland dispute 'strategic wake-up call for all of Europe,' says Macron
-
SKorean chip giant SK hynix posts record operating profit for 2025
-
Greenland's elite dogsled unit patrols desolate, icy Arctic
-
Uganda's Quidditch players with global dreams
-
'Hard to survive': Kyiv's elderly shiver after Russian attacks on power and heat
-
Polish migrants return home to a changed country
-
Dutch tech giant ASML posts bumper profits, eyes bright AI future
-
Minnesota congresswoman unbowed after attacked with liquid
Man who let snakes bite him 200 times spurs new antivenom hope
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.
P.Petrenko--CPN